DDInter1233 DDInter633
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug. Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir.
Mitotane {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sodium bicarbonate
Sodium bicarbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Elvitegravir
Mitotane {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Orlistat
Orlistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Elvitegravir
Mitotane {u} (Compound) binds {v} (Gene) SHBG
SHBG {u} (Gene) is bound by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elvitegravir
Mitotane (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sodium bicarbonate (Compound) and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Mitotane (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Elvitegravir
Mitotane (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Orlistat (Compound) and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Elvitegravir
Mitotane (Compound) binds SHBG (Gene) and SHBG (Gene) is bound by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir